Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1997 Aug;73(862):481–486. doi: 10.1136/pgmj.73.862.481

Testicular carcinoma.

A O'Callaghan 1, G M Mead 1
PMCID: PMC2431367  PMID: 9307739

Abstract

Testicular cancer is the commonest malignancy in young males and its incidence has more than doubled in the last 25 years. For clinical purposes, two tumour types are identified, seminoma and non-seminoma germ cell tumours (loosely known as teratomas). Stage I disease is confined to the testes and is managed surgically, with adjuvant chemotherapy or radiotherapy as appropriate. Cisplatin-based chemotherapy is the cornerstone of treatment for metastatic disease, with cure rates exceeding 80%. Early diagnosis and cure should be the aim in all patients. To this end, those with testicular symptoms should be evaluated promptly by ultrasound, and in young male patients presenting with the clinical picture of metastatic disease, germ cell tumour should top the list of differential diagnoses.

Full text

PDF
481

Images in this article

482Figure 1
on p.482
483Figure 2
on p.483
483Figure 3
on p.483
483Figure 4
on p.483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajorin D. F., Sarosdy M. F., Pfister D. G., Mazumdar M., Motzer R. J., Scher H. I., Geller N. L., Fair W. R., Herr H., Sogani P. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993 Apr;11(4):598–606. doi: 10.1200/JCO.1993.11.4.598. [DOI] [PubMed] [Google Scholar]
  2. Bates S. E., Longo D. L. Use of serum tumor markers in cancer diagnosis and management. Semin Oncol. 1987 Jun;14(2):102–138. [PubMed] [Google Scholar]
  3. Cullen M. H., Stenning S. P., Parkinson M. C., Fossa S. D., Kaye S. B., Horwich A. H., Harland S. J., Williams M. V., Jakes R. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996 Apr;14(4):1106–1113. doi: 10.1200/JCO.1996.14.4.1106. [DOI] [PubMed] [Google Scholar]
  4. Fosså S. D., Aass N., Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):383–388. doi: 10.1016/0360-3016(89)90334-9. [DOI] [PubMed] [Google Scholar]
  5. Freedman L. S., Parkinson M. C., Jones W. G., Oliver R. T., Peckham M. J., Read G., Newlands E. S., Williams C. J. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987 Aug 8;2(8554):294–298. doi: 10.1016/s0140-6736(87)90889-0. [DOI] [PubMed] [Google Scholar]
  6. Garrow G. C., Johnson D. H. Treatment of "good risk" metastatic testicular cancer. Semin Oncol. 1992 Apr;19(2):159–165. [PubMed] [Google Scholar]
  7. Hamilton C., Horwich A., Easton D., Peckham M. J. Radiotherapy for stage I seminoma testis: results of treatment and complications. Radiother Oncol. 1986 Jun;6(2):115–120. doi: 10.1016/s0167-8140(86)80017-2. [DOI] [PubMed] [Google Scholar]
  8. Horwich A., Dearnaley D. P., Duchesne G. M., Williams M., Brada M., Peckham M. J. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol. 1989 Aug;7(8):1150–1156. doi: 10.1200/JCO.1989.7.8.1150. [DOI] [PubMed] [Google Scholar]
  9. Horwich A. Salvage therapy of germ cell tumours. Br J Cancer. 1995 May;71(5):901–903. doi: 10.1038/bjc.1995.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997 Feb;15(2):594–603. doi: 10.1200/JCO.1997.15.2.594. [DOI] [PubMed] [Google Scholar]
  11. Jansen R. L., Sylvester R., Sleyfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., Keizer J., van Oosterom A. T., Meyer S., Vendrik C. P. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer. 1991;27(6):695–698. doi: 10.1016/0277-5379(91)90168-d. [DOI] [PubMed] [Google Scholar]
  12. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  13. Read G., Stenning S. P., Cullen M. H., Parkinson M. C., Horwich A., Kaye S. B., Cook P. A. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992 Nov;10(11):1762–1768. doi: 10.1200/JCO.1992.10.11.1762. [DOI] [PubMed] [Google Scholar]
  14. Rodriguez E., Mathew S., Reuter V., Ilson D. H., Bosl G. J., Chaganti R. S. Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res. 1992 Apr 15;52(8):2285–2291. [PubMed] [Google Scholar]
  15. von der Maase H., Rørth M., Walbom-Jørgensen S., Sørensen B. L., Christophersen I. S., Hald T., Jacobsen G. K., Berthelsen J. G., Skakkebaek N. E. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 1986 Nov 29;293(6559):1398–1401. doi: 10.1136/bmj.293.6559.1398. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES